New antibody drug shows promise for Hard-to-Treat blood cancer
NCT ID NCT03145181
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug, teclistamab, in about 300 people with multiple myeloma (a type of blood cancer) that has returned or stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Teclistamab works by helping the immune system attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Tours Hopital Bretonneau
Tours, 37044, France
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Haematology Centre, R 51
Stockholm, SE-141 86, Sweden
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Hospices Civils de Lyon HCL
Lyon, 69002, France
-
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects
New York, New York, 10029, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
Conditions
Explore the condition pages connected to this study.